COLGATE ORAL PHARMACEUTICALS, INC.

Colgate Oral Pharmaceutical, Inc. specializes in the manufacturing of pharmaceutical preparations, with a focus on developing and supplying regulated drug products for clinical use. Their technical expertise lies in Good Manufacturing Practice (GMP)-compliant production of oral and systemic pharmaceuticals, including formulation development, batch processing, quality control testing, and regulatory documentation aligned with FDA and VA standards. The company demonstrates proficiency in managing the end-to-end lifecycle of pharmaceutical products, from active ingredient integration to final packaging, ensuring stability, potency, and compliance with federal pharmacopeial requirements. Their specialization in hematology-related and specialty drug formulations suggests a focused capability in complex dosage forms requiring precise control over active pharmaceutical ingredients and excipient compatibility. The contractor has delivered pharmaceutical products to the Department of Veterans Affairs under a Federal Supply Schedule contract, indicating established trust in supplying mission-critical medications to veteran healthcare systems. This relationship reflects a proven ability to meet the VA’s stringent requirements for drug sourcing, traceability, and just-in-time distribution across its national network of medical centers and clinics. Their primary industry focus is pharmaceutical preparation manufacturing (NAICS 325412), which encompasses the formulation, blending, and encapsulation of active pharmaceutical ingredients into finished dosage forms such as tablets, capsules, and injectables. This positions them within the niche segment of specialty drug manufacturing, particularly for therapies requiring controlled release profiles or specialized delivery systems used in chronic and hematologic conditions. Colgate Oral Pharmaceutical, Inc. is structured as a 2L entity headquartered in New York, NY, with no federal certifications on record. Their government market presence is defined by direct supply to federal healthcare providers through established procurement channels, leveraging their manufacturing infrastructure to support consistent, compliant delivery of essential therapeutics to public health systems.